Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Moderna, Inc.
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
February 13, 2026
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
February 13, 2026
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
February 12, 2026
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
January 26, 2026
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
January 22, 2026
←
Previous Page
1
2
3
4